Your browser doesn't support javascript.
loading
Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group.
Richter, Trevor; Nestler-Parr, Sandra; Babela, Robert; Khan, Zeba M; Tesoro, Theresa; Molsen, Elizabeth; Hughes, Dyfrig A.
Affiliation
  • Richter T; Canadian Agency for Drugs & Technologies in Health (CADTH), Ottawa, Ontario, Canada. Electronic address: trevorr@cadth.ca.
  • Nestler-Parr S; Roboleo & Co, York, UK.
  • Babela R; St. Elizabeth University, Bratislava, Slovakia.
  • Khan ZM; Celgene Corporation, Summit, NJ, USA.
  • Tesoro T; International Society for Pharmacoeconomics and Outcomes Research (ISPOR), South Lawrenceville, NJ, USA.
  • Molsen E; International Society for Pharmacoeconomics and Outcomes Research (ISPOR), South Lawrenceville, NJ, USA.
  • Hughes DA; Center for Health Economics and Medicines Evaluation, Bangor University, Wales, UK.
Value Health ; 18(6): 906-14, 2015 Sep.
Article in En | MEDLINE | ID: mdl-26409619
ABSTRACT

BACKGROUND:

At present, there is no universal definition of rare disease.

OBJECTIVE:

To provide an overview of rare disease definitions currently used globally.

METHODS:

We systematically searched for definitions related to rare disease from organizations in 32 international jurisdictions. Descriptive statistics of definitions were generated and prevalence thresholds were calculated.

RESULTS:

We identified 296 definitions from 1109 organizations. The terms "rare disease(s)" and "orphan drug(s)" were used most frequently (38% and 27% of the definitions, respectively). Qualitative descriptors such as "life-threatening" were used infrequently. A prevalence threshold was specified in at least one definition in 88% of the jurisdictions. The average prevalence threshold across organizations within individual jurisdictions ranged from 5 to 76 cases/100,000 people. Most jurisdictions (66%) had an average prevalence threshold between 40 and 50 cases/100,000 people, with a global average of 40 cases/100,000 people. Prevalence thresholds used by different organizations within individual jurisdictions varied substantially. Across jurisdictions, umbrella patient organizations had the highest (most liberal) average prevalence threshold (47 cases/100,000 people), whereas private payers had the lowest threshold (18 cases/100,000 people).

CONCLUSIONS:

Despite variation in the terminology and prevalence thresholds used to define rare diseases among different jurisdictions and organizations, the terms "rare disease" and "orphan drug" are used most widely and the average prevalence threshold is between 40 and 50 cases/100,000 people. These findings highlight the existing diversity among definitions of rare diseases, but suggest that any attempts to harmonize rare disease definitions should focus on standardizing objective criteria such as prevalence thresholds and avoid qualitative descriptors.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Global Health / Rare Diseases / Terminology as Topic Type of study: Diagnostic_studies / Etiology_studies / Guideline / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limits: Humans Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2015 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Global Health / Rare Diseases / Terminology as Topic Type of study: Diagnostic_studies / Etiology_studies / Guideline / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limits: Humans Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2015 Document type: Article